Q2 EPS Forecast for Ovid Therapeutics Reduced by Analyst

Ovid Therapeutics (NASDAQ:OVID) – Analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Ovid Therapeutics in a report released on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.10) per share for the quarter, down from their prior estimate of ($0.08). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.41) EPS and FY2027 earnings at ($0.35) EPS.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). Ovid Therapeutics had a negative return on equity of 22.51% and a negative net margin of 240.11%.

A number of other equities research analysts also recently commented on OVID. Wall Street Zen upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Tuesday, April 21st. Wedbush restated an “outperform” rating and issued a $7.00 target price on shares of Ovid Therapeutics in a research report on Wednesday, April 15th. Roth Mkm restated a “buy” rating and issued a $7.00 target price on shares of Ovid Therapeutics in a research report on Thursday, May 14th. Finally, BTIG Research restated a “buy” rating and issued a $4.00 target price on shares of Ovid Therapeutics in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Ovid Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $5.13.

Ovid Therapeutics Price Performance

NASDAQ:OVID opened at $2.54 on Thursday. Ovid Therapeutics has a 52 week low of $0.27 and a 52 week high of $3.11. The company has a quick ratio of 10.17, a current ratio of 10.17 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $474.07 million, a P/E ratio of -8.76 and a beta of 0.18. The stock’s fifty day moving average is $2.57 and its two-hundred day moving average is $1.95.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC acquired a new position in Ovid Therapeutics during the 1st quarter worth $23,732,000. Ally Bridge Group NY LLC grew its stake in Ovid Therapeutics by 57.9% during the 1st quarter. Ally Bridge Group NY LLC now owns 2,818,459 shares of the company’s stock worth $6,257,000 after purchasing an additional 1,033,459 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in Ovid Therapeutics by 6.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 4,544,113 shares of the company’s stock worth $10,088,000 after purchasing an additional 259,113 shares in the last quarter. Affinity Asset Advisors LLC grew its stake in Ovid Therapeutics by 48.8% during the 1st quarter. Affinity Asset Advisors LLC now owns 10,636,318 shares of the company’s stock worth $23,613,000 after purchasing an additional 3,486,318 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in Ovid Therapeutics during the 1st quarter worth $730,000. 72.24% of the stock is owned by institutional investors and hedge funds.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.